Therefore, we postulate that research on ADHD should broaden its scope by including the temporal lobe as a potentially important locus of abnormalities in ADHD. (c) 2010 Elsevier Ireland Ltd. All rights reserved.”
“Type I interferons (IFNs), predominantly IFN-alpha and -beta, play critical roles in both innate and

adaptive immune responses against viral infections. Interferon regulatory factor 7 (IRF7), a key innate immune molecule in the type I IFN signaling pathway, is essential for the type I IFN response to many viruses, including lymphocytic choriomeningitis virus (LCMV). Here, we show that although IRF7 knockout (KO) mice failed to control the replication of LCMV in the early stages of infection, they were capable of clearing LCMV infection. Despite the see more lack of type I IFN production, IRF7 KO mice generated normal CD4(+) T cell responses, and the expansion of naive CD8(+) T cells into primary CD8(+) T cells specific for LCMV GP(33-41) was relatively normal. In contrast, the expansion of the LCMV NP396-specific CD8(+) T cells was severely impaired in IRF7 KO mice.

We demonstrated that this defective selleck compound CD8(+) T cell response is due neither to an impaired antigen-presenting system nor to any intrinsic role of IRF7 in CD8(+) T cells. The lack of a type I IFN response in IRF7 KO mice did not affect the formation of memory CD8(+) T cells. Thus, the present study provides new insight into the impact of the innate immune system on viral pathogenesis and demonstrates the critical contribution of innate immunity in controlling virus replication in the early stages of infection, which may shape the quality of CD8(+) T cell responses.”
“The basolateral amygdala (BLA) and infralimbic (IL) cortex share strong reciprocal interconnections and are key structures in conditioned fear circuitry. Gastrin-releasing peptide (GRP) or its receptor antagonists can modulate the PDK4 conditioned fear response when exogenously administered at either of these sites, and increased release of GRP at the BLA occurs in response

to conditioned fear recall. The present study sought to determine whether a functional pathway utilizing GRP exists between the IL cortex and BLA and whether this pathway is also influenced by amygdala corticotropin-releasing factor (CRF) release. To this end, we assessed the effects of intra-IL cortex injection of GRP or GRP co-administered with a receptor antagonist, RC-3095, on the downstream release of GRP and/or CRF at the BLA. Results showed that microinjection of GRP at the IL cortex increased the release of GRP, but not CRF, at the BLA, an effect blocked by co-administration of RC-3095. Administration of RC-3095 into the IL cortex on its own, however, also elicited the release of GRP (but not CRF) at the BLA. These findings suggest that a functional pathway utilizing GRP (among other factors) exists between the IL cortex and BLA that may be relevant to conditioned fear, but that GRP and CRF do not interact within this circuitry.